Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Temazepam has a high potential for psychological addiction and is considered significantly more addictive than other benzodiazepines. It produces euphoria more commonly than most benzodiazepines and has the highest preference ratings among recreational drug users due to its rapid onset, perceived strength, and subjective 'high'.
Physical dependence develops readily with regular use, and abrupt discontinuation can be life-threatening, potentially resulting in severe withdrawal syndrome, seizures, or death. Withdrawal symptoms can occur even from standard therapeutic doses after short-term use. Gradual tapering under medical supervision is essential for cessation.
Temazepam has the highest fatal toxicity index among commonly prescribed benzodiazepines and is notably the only benzodiazepine documented to cause fatal overdoses without combination with other CNS depressants. A 1993 British study found 11.9 deaths per million prescriptions compared to 5.9 for benzodiazepines overall. Temazepam overdose is significantly more likely to result in coma than other benzodiazepines (odds ratio 1.86). Despite benzodiazepines generally having a high therapeutic index, temazepam is considered one of the more dangerous members of this class.
Pronounced CNS depression occurs at therapeutic doses, including impairment of memory, learning, motor coordination, and reaction time; at higher doses or in overdose, confusion, coma, and absent reflexes may develop.
Respiratory depression can occur at higher doses and has proven fatal even when temazepam is taken alone, which is unusual among benzodiazepines.
Severe hepatic impairment decreases temazepam elimination by approximately half; hyperplastic liver nodules were observed in female mice at the highest doses in animal studies.
Psychotic states have been reported rarely in the medical literature following abrupt withdrawal from benzodiazepines, even from therapeutic doses. Hallucinations are listed as a less common side effect occurring in under 0.5% of users. Paradoxical reactions including aggression, violent behavior, and agitation occur rarely, with an incidence below 1% in the general population.
Sudden discontinuation after regular use can result in potentially life-threatening seizures; this risk is a primary concern with benzodiazepine withdrawal and necessitates gradual tapering rather than abrupt cessation. Paradoxical increased seizure activity may occur in epileptic individuals. Antipsychotics increase the severity of withdrawal convulsions.
Temazepam was patented in 1962, with its chemical synthesis established by the mid-1960s. While the compound entered medical use in 1969, its specific application as a treatment for insomnia was not fully recognized until 1981. By the late 1980s, temazepam had become one of the most popular and
UN Convention on Psychotropic Substances 1971 (Schedule IV)
Designated as a prescription-only medicine under Australian scheduling regulations. Cannot be legally obtained without a valid prescription from a registered medical practitioner.
Controlled under Schedule IV of the Controlled Drugs and Substances Act. Requires a prescription for lawful possession. Available in various generic and brand formulations through licensed pharmacies.
Classified as a Schedule 1 controlled substance. Subject to strict regulatory controls on possession, prescribing, and dispensing.
Controlled under List II of the Opium Law. Available through prescription for approved medical indications. Preparation, possession, delivery, and transport without authorization are prohibited, though possession of small quantities for personal use is typically not prosecuted.
Designated as a Schedule III controlled substance since 2013. Subject to regulatory controls on medical prescribing and distribution.
Classified as a prescription medication under List IV (Schedule 4) of the Narcotics Drugs Act of 1968. Legal only with valid medical prescription.
Listed in Schedule II of the Psychotropic Substances Act. Subject to controls on importation, manufacture, possession, and distribution.
Assigned to Schedule IV of the Controlled Substances Act by the DEA, indicating accepted medical use with lower abuse potential compared to Schedule III substances. Possession without valid prescription and unlicensed sale are federal offenses. Several states require specially encoded prescriptions due to historical misuse concerns.
Permitted for medical use under the Arzneimittelgesetz (Medicines Act). Possession or sale without a valid prescription constitutes an offense under the Suchtmittelgesetz (Addictive Substances Act).
Listed in Anlage III of the Betäubungsmittelgesetz (Narcotics Act) since August 1, 1986. Prescriptions must be written on special narcotic prescription forms, except for preparations containing 20 mg or less per dosage unit.
Added to Schedule 3 of the Misuse of Drugs Act 1977 on November 22, 1993. Possession without authorization and unauthorized supply are criminal offenses.
Classified as a Schedule IV controlled substance under national drug legislation. Available for medical use with appropriate prescription.
Listed as a Schedule 5 controlled substance. Possession and supply are regulated under national pharmaceutical and narcotics legislation.
Specifically listed under Verzeichnis B (Schedule B) of controlled substances regulations. Medicinal use is permitted with appropriate prescription from authorized practitioners.
Controlled as a Class C substance under the Misuse of Drugs Act 1971. Possession without prescription carries a maximum penalty of 2 years imprisonment and/or a fine. Unauthorized supply is punishable by up to 5 years imprisonment and/or a fine. Medical professionals must follow specific protocols for prescribing and disposal.
11 sources cited